We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Graybug Vision Inc (GRAY) USD0.0001

Sell:$0.94 Buy:$0.97 Change: $0.11 (10.09%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.11 (10.09%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.11 (10.09%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The Company's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The Company is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.

Contact details

203 Redwood Shores Parkway, Suite 620
United States
+1 (650) 4872800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$23.50 million
Shares in issue:
21.36 million
United States
US dollar

Key personnel

  • Frederic Guerard
    President, Chief Executive Officer, Director
  • Robert Breuil
    Chief Financial Officer
  • Parisa Zamiri
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.